


Reference Data

(Consolidated Financial Results for Q4 FY2023)



Daiichi-Sankyo

April 25, 2024

Daiichi Sankyo Co., Ltd.

<https://www.daiichisankyo.com>

Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Sheet to adjust Operating Profit to Core Operating Profit	P2
3.	Revenue of Global Products	P3
4.	Revenue by Business Units and Products	P5
5.	Consolidated Statement of Financial Position	P8
6.	Consolidated Statement of Cash Flows	P10
7.	Number of Employees	P11
8.	Capital Expenditure, Depreciation and Amortization	P11
9.	Other Financial Indicators	P11
10.	Summary of Product Outlines	P12
11.	Quarterly Data	P13
12.	Historical Data	P19
13.	Major R&D Pipeline (Innovative pharmaceuticals)	P23

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2022		FY2023					FY2024			
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast	YoY	YoY (%)
Revenue	100.0%	1,278.5	100.0%	1,601.7	101.4%	323.2	+25.3%	100.0%	1,750.0	148.3	+9.3%
Cost of sales*1	27.3%	349.1	25.9%	414.8	100.4%	65.7	+18.8%	22.6%	395.0	-19.8	-4.8%
Gross Profit	72.7%	929.4	74.1%	1,186.9	101.7%	257.5	+27.7%	77.4%	1,355.0	168.1	+14.2%
SG&A expenses*1	36.8%	470.1	39.2%	627.3	101.3%	157.2	+33.4%	38.6%	675.0	47.7	+7.6%
DXd ADC profit share*2	7.1%	90.8	10.6%	170.6	-	79.8	+87.8%	11.1%	193.6	23.0	+13.5%
Other SG&A expenses	29.7%	379.3	28.5%	456.8	-	77.5	+20.4%	27.5%	481.4	24.6	+5.4%
R&D expenses*1	26.3%	336.7	22.7%	364.3	99.0%	27.6	+8.2%	26.9%	470.0	105.7	+29.0%
Core Operating Profit	9.6%	122.6	12.2%	195.3	108.5%	72.7	+59.3%	12.0%	210.0	14.7	+7.5%
Temporary income*3		21.9		27.3		5.4			20.0	-7.3	
Temporary expenses*3		23.9		10.9		-13.0			-	-10.9	
Operating Profit	9.4%	120.6	13.2%	211.6	105.8%	91.0	+75.5%	13.1%	230.0	18.4	+8.7%
Financial income/expenses		6.3		25.5		19.2					
Share of profit or loss of investments accounted for using the equity method		-0.0		0.2		0.2					
Profit before tax	9.9%	126.9	14.8%	237.2	115.7%	110.4	+87.0%	13.4%	235.0	-2.2	-0.9%
Income taxes		17.7		36.2		18.6					
Profit for the year	8.5%	109.2	12.6%	201.0	114.9%	91.8	+84.1%	10.9%	190.0	-11.0	-5.5%
Profit attributable to owners of the Company	8.5%	109.2	12.5%	200.7	114.7%	91.5	+83.8%	10.9%	190.0	-10.7	-5.3%
Tax rate		13.9%		15.3%							
Overseas sales ratio		58.3%		62.5%							
Currency Rate (Average)											
USD/JPY		135.48		144.62					145.00		
EUR/JPY		140.97		156.79					155.00		

Forex impact: +66.8
(USD: +29.6, EUR: +29.0, ASCA: +8.2)

Forex impact: +12.6
(USD: +7.2, EUR: +4.6, ASCA: +0.8)

Forex impact: +26.2
(USD: +16.3, EUR: +7.6, ASCA: +2.3)

Forex impact: +17.4
(USD: +13.0, EUR: +4.0, ASCA: +0.4)

Forex impact: +10.6
(USD: -6.8, EUR: +12.7, ASCA: +4.7)

- Increase of interest income +13.6
- Improvement in investment securities valuation gains/losses +6.2

Annual impact of JPY 1 change

	Forecast	
	USD	EUR
Revenue	JPY 4.3 Bn	JPY 2.3 Bn
Operating Profit	JPY -0.2 Bn	JPY 0.3 Bn

This report is not subject to audit procedures.

*1 Temporary income and expenses are excluded for cost of sales, SG&A expenses and R&D expenses

*2 DS pays alliance partners 50% of gross profit for the product sales in countries/regions where DS book revenue (excluding Japan) to share profit with the partners

*3 See page 2 for the definition of temporary income and expenses and the adjustment of operating profit and core operating profit

2. Sheet to adjust Operating Profit to Core Operating Profit

FY2022 Results

JPY Bn	Full base	Adjustment					Core base
		gains and losses related to sale of fixed assets	gains and losses related to restructuring	gains and losses related to impairment,	gains and losses related to loss compensation, reconciliation	Others	
Revenue	1,278.5						1,278.5
Cost of sales	363.5			-14.2		-0.3	349.1
SG&A expenses	471.2			-0.0		-1.1	470.1
R&D expenses	341.6			-4.8		-0.0	336.7
Other income*	19.1	-12.8	-5.9			-0.4	-
Other expenses*	0.7	-0.0	-0.7				-
Core Operating Profit**							122.6
Temporary income		12.8 ^{*1}	5.9 ^{*2}	3.2 ^{*3}			21.9
Temporary expenses		0.0	0.7	22.3 ^{*4}		0.9	23.9
Operating Profit (full)	120.6						120.6

<Major Temporary income and Temporary expenses>

^{*1} Gains related to sale of fixed assets of Kyushu Branch Building etc.

^{*2} Gains related to sales of subsidiary of Daiichi Sankyo (China)

^{*3} Gains on reversal related to the closure of Plexxikon

^{*4} Losses related to impairment of Intangible assets of Turalio, DS-5141, Penthorox

FY2023 Results

JPY Bn	Full base	Adjustment					Core base
		gains and losses related to sale of fixed assets	gains and losses related to restructuring	gains and losses related to impairment,	gains and losses related to loss compensation, reconciliation	Others	
Revenue	1,601.7						1,601.7
Cost of sales	415.3			-0.5		-0.1	414.8
SG&A expenses	637.0		-0.4		-2.7	-6.5	627.3
R&D expenses	365.2		-0.3			-0.5	364.3
Other income*	27.5	-0.2			-27.1	-0.2	-
Other expenses*	0.1	-0.1					-
Core Operating Profit**							195.3
Temporary income		0.2			27.1 ^{*5}		27.3
Temporary expenses		0.1	0.7	0.5	2.7	6.9 ^{*6}	10.9
Operating Profit (full)	211.6						211.6

<Major Temporary income and Temporary expenses>

^{*5} Settlement payment for Plexxikon

related to patent dispute with Novartis (26.4)

^{*6} Environmental expenditures related to former Yasugawa plant (4.1)

* The Company discloses profit and loss for which the offsetting of income and expenses is not permitted as Other income and Other expenses in the consolidated statement of income on a full basis (IFRS standards). Profit and loss from the sale of assets, etc. are included in this Other income and Other expenses.

** As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses".

3. Revenue of Global Products (1)

JPY Bn	FY2022	FY2023				FY2024		
	Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Trastuzumab deruxtecan <small>anti-cancer agent (HER2-directed antibody drug conjugate)</small>	258.4	449.2	(102.9%)	190.8	+73.9%	585.4	136.2	+30.3%
Product sales <small>*Incl. Gross profit share in AstraZeneca territory</small>	207.5	395.9	(103.1%)	188.4	+90.8%	508.4	112.4	+28.4%
Enhertu (JPN)	11.7	23.9	(104.9%)	12.2	+104.1%	25.7	1.8	+7.5%
Enhertu (US)	144.6	225.5	(99.7%)	81.0	+56.0%	266.6	41.1	+18.2%
Enhertu (EU)	37.1	101.9	(107.8%)	64.8	+174.9%	152.1	50.2	+49.2%
Enhertu (ASCA: Asia, South and Central America)	14.2	44.6	(110.8%)	30.4	+214.4%	64.0	19.4	+43.5%
Brazil	9.7	23.5	-	13.8	+142.9%	29.9	6.4	+27.2%
China (co-promotion revenue)	-	6.5	-	6.5	-	10.8	4.3	+65.2%
Others	4.5	14.6	-	10.1	+223.0%	23.3	8.7	+60.0%
Upfront payment	9.8	10.1	(100.0%)	0.3	+2.9%	10.2	0.1	0.0
Regulatory milestone payment	26.7	12.4	(100.0%)	-14.3	-53.7%	9.4	-2.9	-23.7%
US HER2+ Breast Cancer 3L	0.9	0.9	(100.0%)	0.0	+3.0%	0.9	0.0	0.0
EU HER2+ Breast Cancer 3L	0.5	0.5	(100.0%)	0.0	+3.0%	0.5	0.0	0.0
US HER2+ Gastric Cancer 2L/3L	0.8	0.8	(100.0%)	0.0	+3.0%	0.8	0.0	0.0
US HER2+ Breast Cancer 2L	3.5	0.9	(100.0%)	-2.6	-74.3%	0.9	0.0	+1.0%
EU HER2+ Breast Cancer 2L	2.7	0.7	(100.0%)	-2.0	-74.3%	0.7	0.0	+1.0%
US HER2-low Breast Cancer (post chemo)	7.3	1.9	(100.0%)	-5.4	-74.3%	1.9	0.0	+1.0%
EU HER2-low Breast Cancer (post chemo)	5.2	1.3	(100.0%)	-3.9	-74.3%	1.4	0.0	+1.0%
EU HER2+ Gastric Cancer 2L	1.3	0.3	(100.0%)	-0.9	-74.3%	0.3	0.0	+1.0%
US HER2 mutant NSCLC 2L	4.6	1.2	(100.0%)	-3.4	-74.3%	1.2	0.0	+1.0%
EU HER2 mutant NSCLC 2L	-	3.8	(100.0%)	3.8	-	0.8	-3.0	-80.0%
Quid related payment*	1.1	1.2	(100.0%)	0.0	+3.0%	1.2	0.0	+1.0%
Sales milestone payment	13.2	29.6	(102.2%)	16.5	+124.8%	56.2	26.6	+89.6%

*Payment which shall be paid by AstraZeneca to Daiichi Sankyo if both parties do not enter into potential licensing opportunity (Granting Daiichi Sankyo rights to develop or commercialize AstraZeneca's proprietary products, programs or technologies)

3. Revenue of Global Products (2)

JPY Bn		FY2022	FY2023				FY2024		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
	Datopotamab deruxtecan anti-cancer agent (TROP2-directed antibody drug conjugate)	7.1	6.4	(100.0%)	-0.7	-9.8%	17.6	11.2	+175.8%
	Product sales *Incl. Gross profit share in AstraZeneca territory	-	-	-	-	-	5.6	5.6	-
	Datopotamab deruxtecan (US)	-	-	-	-	-	5.6	5.6	-
	Upfront payment	7.1	6.4	(100.0%)	-0.7	-9.8%	6.4	-	+0.0%
	Regulatory milestone payment	-	-	-	-	-	5.6	5.6	-
	US NSCLC 2L/3L	-	-	-	-	-	5.6	5.6	-
	Patritumab deruxtecan anti-cancer agent (HER3-directed antibody drug conjugate)	-	3.5	(100.0%)	3.5	-	23.1	19.6	+553.1%
	Product sales *Incl. Gross profit share in Merck territory	-	-	-	-	-	4.2	4.2	-
	Patritumab deruxtecan (US)	-	-	-	-	-	4.2	4.2	-
	Upfront payment	-	3.5	(100.0%)	3.5	-	18.9	15.4	+434.2%
	Ifinatamab deruxtecan anti-cancer agent (DS-7300) (B7-H3-directed antibody drug conjugate)	-	6.6	(100.0%)	6.6	-	14.7	8.1	+553.1%
	Upfront payment	-	6.6	(100.0%)	6.6	-	14.7	8.1	+434.2%
	Raludotatug deruxtecan anti-cancer agent (DS-6000) (CDH6-directed antibody drug conjugate)	-	2.8	(100.0%)	2.8	-	6.2	3.4	+122.8%
	Upfront payment	-	2.8	(100.0%)	2.8	-	6.2	3.4	+122.8%
	Edoxaban anticoagulant	244.0	287.7	(102.1%)	43.8	+17.9%	293.6	5.9	+2.1%
	Lixiana (JPN)	105.1	115.6	(101.0%)	10.4	+9.9%	116.4	0.8	+0.7%
	Savaysa (US)	3.0	2.4	(81.1%)	-0.6	-19.5%	2.8	0.4	+16.6%
	Lixiana (EU)	117.1	146.2	(102.8%)	29.1	+24.8%	149.5	3.3	+2.2%
	Edoxaban (ASCA* etc.)	18.7	23.5	(105.8%)	4.8	+25.7%	24.9	1.4	+6.0%

*Asia, South and Central America

4. Revenue by Business Units and Products (1)

JPY Bn

		FY2022	FY2023				FY2024		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Japan Business Unit		457.9	518.9	(100.8%)	61.0	+13.3%	434.9	-84.0	-16.2%
Lixiana	anticoagulant	105.1	115.6	(101.0%)	10.4	+9.9%	116.4	0.8	+0.7%
Pralia	Treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	40.2	42.8	(101.3%)	2.6	+6.5%	39.3	-3.5	-8.3%
Tarlige	pain treatment	38.5	45.7	(100.9%)	7.2	+18.6%	53.4	7.7	+16.9%
Vimpat	anti-epileptic agent	21.9	25.7	(99.7%)	3.8	+17.3%	29.2	3.5	+13.5%
Ranmark	treatment for bone complications caused by bone metastases from tumors	20.4	20.4	(98.2%)	-0.0	-0.0%	20.7	0.3	+1.6%
Tenelia	type 2 diabetes mellitus treatment	21.9	20.5	(99.5%)	-1.5	-6.8%	9.6	-10.9	-53.1%
Enhertu	anti-cancer agent (HER2-directed antibody drug conjugate)	11.7	23.9	(104.9%)	12.2	+104.1%	25.7	1.8	+7.5%
Efient	antiplatelet agent	20.9	25.6	(101.9%)	4.7	+22.6%	16.2	-9.4	-36.7%
Canalia	type 2 diabetes mellitus treatment	16.3	15.9	(99.7%)	-0.4	-2.4%	15.0	-0.9	-5.8%
Loxonin	anti-inflammatory analgesic	18.5	15.5	(100.7%)	-3.0	-16.4%	12.7	-2.8	-17.9%
Emgality	prophylaxis of migraine attacks	6.3	7.6	(103.2%)	1.3	+21.2%	8.8	1.2	+16.0%
Inavir	anti-influenza treatment	0.9	15.9	(103.8%)	15.0	-	11.3	-4.6	-28.9%
Minnebro	antihypertensive agent	6.9	8.3	(101.1%)	1.4	+20.4%	10.8	2.5	+30.3%
Daiichi Sankyo Espha products		86.0	83.0	-	-3.1	-3.6%	not disclosed	-	-
Vaccines business		13.4	27.7	-	14.3	+106.3%	not disclosed	-	-
Daiichi Sankyo Healthcare Unit		70.3	76.0	(101.8%)	5.6	+8.0%	82.7	6.7	+8.9%

4. Revenue by Business Units and Products (2)

JPY Bn		FY2022	FY2023				FY2024		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Oncology Business Unit		185.4	334.6	(102.1%)	149.2	+80.5%	442.6	108.0	+32.3%
	Enhertu	181.6	327.4	(102.1%)	145.8	+80.3%	418.7	91.2	+27.9%
	Enhertu (US)	144.6	225.5	(99.7%)	81.0	+56.0%	266.6	41.1	+18.2%
	Enhertu (EU)	37.1	101.9	(107.8%)	64.8	+174.9%	152.1	50.2	+49.2%
	Datopotamab deruxtecan (US)	-	-	-	-	-	5.6	5.6	-
	Patritumab deruxtecan (US)	-	-	-	-	-	4.2	4.2	-
	TURALIO	3.8	5.3	(100.0%)	1.5	+39.9%	5.8	0.5	+8.7%
American Regent Unit		187.4	203.4	(98.8%)	16.1	+8.6%	218.2	14.8	+7.3%
	Injectafer	54.0	50.1	(98.5%)	-3.9	-7.2%	49.7	-0.3	-0.7%
	Venofer	51.3	60.9	(101.9%)	9.6	+18.7%	58.0	-2.9	-4.7%
	GE injectables	71.6	81.0	(98.7%)	9.4	+13.2%	95.7	14.7	+18.1%
EU Specialty Business Unit		150.4	189.2	(103.0%)	38.8	+25.8%	201.4	12.3	+6.5%
	Lixiana	117.1	146.2	(102.8%)	29.1	+24.8%	149.5	3.3	+2.2%
	Nilemdo/Nustendi	7.1	18.4	(101.8%)	11.4	+160.8%	33.6	15.2	+82.4%
	Olmesartan	20.0	19.6	(104.4%)	-0.4	-2.1%	15.6	-4.0	-20.4%
ASCA Business Unit		142.8	184.1	(104.7%)	41.3	+28.9%	188.2	4.1	+2.2%
	Daiichi Sankyo China	58.3	70.5	(107.0%)	12.2	+20.9%	61.2	-9.3	-13.1%
	Daiichi Sankyo Korea	25.6	29.2	(96.9%)	3.7	+14.3%	30.0	0.8	+2.7%
	Daiichi Sankyo Brasil Farmacêutica	27.8	42.0	(106.0%)	14.2	+51.2%	50.0	8.0	+19.1%
	Daiichi Sankyo Taiwan	13.3	16.0	(103.9%)	2.7	+20.5%	16.4	0.4	+2.3%
	Daiichi Sankyo Thailand	2.9	3.5	(104.4%)	0.6	+20.4%	3.4	-0.1	-2.8%
	Daiichi Sankyo Hong Kong	3.5	2.9	(106.1%)	-0.6	-17.6%	2.7	-0.2	-6.0%

4. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

		FY2022	FY2023				FY2024		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
USD Mn									
Oncology Business Unit		1,369	2,314	(101.4%)	945	+69.1%	3,052	738	+31.9%
Enhertu	anti-cancer agent (HER2-directed antibody drug conjugate)	1,341	2,264	(101.4%)	923	+68.9%	2,887	623	+27.5%
Enhertu (US)		1,067	1,560	(99.0%)	492	+46.1%	1,839	279	+17.9%
Enhertu (EU)		274	704	(107.1%)	431	+157.6%	1,049	344	+48.9%
Datopotamab deruxtecan (US)	anti-cancer agent (TROP2-directed antibody drug conjugate)	-	-	-	-	-	39	39	-
Patritumab deruxtecan (US)	anti-cancer agent (HER3-directed antibody drug conjugate)	-	-	-	-	-	29	29	-
TURALIO	anti-cancer agent	28	37	(99.4%)	9	+31.1%	40	3	+8.4%
USD Mn									
American Regent Unit		1,383	1,407	(98.2%)	24	+1.7%	1,505	98	+7.0%
Injectafer	treatment for iron deficiency anemia	398	346	(97.9%)	-52	-13.1%	343	-3	-0.9%
Venofer	treatment for iron deficiency anemia	379	421	(101.3%)	42	+11.2%	400	-21	-5.0%
GE injectables		529	560	(98.1%)	32	+6.0%	660	100	+17.8%
EUR Mn									
EU Specialty Business Unit		1,067	1,207	(102.0%)	140	+13.1%	1,300	93	+7.7%
Lixiana	anticoagulant	831	933	(101.7%)	102	+12.2%	964	32	+3.4%
Nilembo/Nustendi	cholesterol-lowering agent	50	118	(100.7%)	67	+134.5%	217	99	+84.5%
Olmесartan	antihypertensive agent	142	125	(103.3%)	-17	-12.0%	101	-24	-19.5%

5. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2023	Mar. 2024	vs. Mar. 2023
Assets			
Current assets			
Cash and cash equivalents	441.9	647.2	205.3
Trade and other receivables	349.1	454.2	105.1
Other financial assets	383.2	577.0	193.8
Inventories	301.6	438.1	136.5
Other current assets	19.2	33.0	13.8
Subtotal	1,495.1	2,149.5	654.5
Assets held for sale	-	24.5	24.5
Total current assets	1,495.1	2,174.0	679.0
Non-current assets			
Property, plant and equipment	348.9	421.7	72.8
Goodwill	98.3	108.5	10.2
Intangible assets	159.6	168.3	8.7
Investments accounted for using the equity method	1.3	0.6	-0.7
Other financial assets	130.4	147.9	17.5
Deferred tax assets	180.1	249.4	69.3
Other non-current assets	95.2	190.7	95.6
Total non-current assets	1,013.8	1,287.1	273.3
Total assets	2,508.9	3,461.1	952.2

Transfer of DSEP assets held for sale +23.5

Acquisition +98.4, Depreciation -39.7, Forex +16.6

Forex +10.2

Acquisition +28.0, Depreciation -19.7, Forex +13.3, Transfer to Assets held for sale (DSEP) -8.7

Investment securities +21.2

Contribution for equipment +70.4

*	Liquidity on hand (Cash, Securities, Investment securities etc.)	824.4	1,223.6	399.3
	Debt with interest	192.9	156.0	-36.9
	Net Cash	631.5	1,067.6	436.1

<Liabilities and equity>

JPY Bn

	Mar. 2023	Mar. 2024	vs. Mar. 2023	
Liabilities				
Current liabilities				
Trade and other payables	395.2	557.1	162.0	
Bonds and borrowings	41.4	0.4	-41.0	Bonds -20.0, Short-term borrowings -21.0
Other financial liabilities	11.1	12.8	1.7	
Income taxes payable	21.5	46.4	24.9	
Provisions	7.6	15.4	7.8	
Contract liabilities	28.9	57.4	28.6	
Other current liabilities	24.7	22.3	-2.3	
Subtotal	530.3	711.9	181.7	
Liabilities directly associated with assets held for sale	-	11.5	11.5	Transfer of liabilities associated with DSEP assets held for sale +11.2
Total current liabilities	530.3	723.4	193.1	
Non-current liabilities				
Bonds and borrowings	101.7	101.3	-0.4	
Other financial liabilities	41.6	46.2	4.6	
Post employment benefit liabilities	1.3	1.3	-0.0	
Provisions	16.4	14.0	-2.4	Deferred revenue for trastuzumab deruxtecan -12.5 (Strategic collaboration upfront payment -10.1, Regulatory milestone payment/Quid -2.4)
Contract liabilities	292.2	680.2	387.9	Deferred revenue for datopotamab deruxtecan -6.4 (Strategic collaboration upfront payment -6.4)
Deferred tax liabilities	12.6	12.9	0.2	Deferred revenue related to strategic collaboration with MRK: Merck & Co., Inc., Rahway, NJ, USA +437.9 (Upfront payment)
Other non-current liabilities	66.9	193.3	126.4	R&D expenses related refundable upfront payment from MRK +150.3
Total non-current liabilities	532.8	1,049.1	516.4	
Total liabilities	1,063.0	1,772.5	709.5	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	-	
Capital surplus	-	2.0	2.0	
Treasury shares	-36.8	-36.6	0.2	
Other components of equity	200.9	284.0	83.1	Currency translation difference +75.5, Valuation difference on financial assets +8.3
Retained earnings	1,231.8	1,388.8	157.1	Profit for the period +200.7, Payment of dividends -67.1
Total equity attributable to owners of the Company	1,445.9	1,688.2	242.3	
Non-controlling interests	-	0.4	0.4	
Total equity	1,445.9	1,688.6	242.7	
Total liabilities and equity	2,508.9	3,461.1	952.2	

6. Consolidated Statement of Cash Flows

JPY Bn

	FY2022	FY2023	YoY
Cash flows from operating activities			
Profit before tax	126.9	237.2	110.4
Depreciation and amortization	67.8	59.6	-8.1
(Increase) decrease in receivables and payables	-10.4	78.3	88.8
Others, net	-23.4	320.8	344.2
Income taxes paid	-46.2	-96.8	-50.5
Net cash flows from operating activities	114.5	599.3	484.7
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	-185.9	-173.8	12.1
(Acquisition of) proceeds from sales of fixed assets	-56.7	-117.5	-60.7
Payments for acquisition of subsidiaries	-30.8	-6.9	23.9
Proceeds from sale of subsidiaries	8.3	7.5	-0.8
Net (increase) decrease in investment securities	-0.3	8.9	9.2
Others, net	7.7	-0.8	-8.5
Net cash flows from investing activities	-257.8	-282.6	-24.9
Cash flows from financing activities			
Net (increase) decrease in borrowings	-20.4	-20.9	-0.5
Repayments of bonds	-	-20.0	-20.0
Purchase of treasury shares	-0.0	-0.0	-0.0
Dividends paid	-54.6	-67.1	-12.5
Others, net	-14.6	-15.5	-1.0
Net cash flows from financing activities	-89.6	-123.6	-34.0
Net increase (decrease) in cash and cash equivalents	-232.9	193.1	425.9
Cash and cash equivalents at the beginning of the period	662.5	441.9	-220.6
Effect of exchange rate changes on cash and cash equivalents	12.3	21.4	9.1
Cash and cash equivalents at the end of the period	441.9	656.4	214.5
Transfer to Assets held for sale	-	-9.2	-9.2
Cash and cash equivalents at the end of the period (Amount on Consolidated Statement of Financial Position)	441.9	647.2	205.3
* Free cash flows (Cash flows from operating activities and investing activities)	-143.3	316.6	459.9

Payment from MRK +601.0
(Upfront payment, R&D expenses related refundable upfront payment)

7. Number of Employees

	Mar. 2023	Mar. 2024
	Results	Results
Consolidated	17,435	18,726
Japan	9,263	9,468
North America	3,062	3,573
Europe	2,554	2,901
Others	2,556	2,784

8. Capital Expenditure, Depreciation and Amortization

		FY2022	FY2023	FY2024
	JPY Bn	Results	Results	Forecast
Capital expenditure		71.5	89.4	79.0
Depreciation and amortization		67.8	59.6	67.7
Property, plant and equipment		36.3	39.9	-
Intangible assets		31.4	19.8	-

9. Other Financial Indicators

	FY2022		FY2023	
	Results		Results	
Profit attributable to owners of the Company	109.2	JPY Bn	200.7	JPY Bn
Dividends	57.5	JPY Bn	95.9	JPY Bn
Average equity attributable to owners of the Company for the period	1,398.4	JPY Bn	1,567.0	JPY Bn
Return on Equity (ROE)	7.8	%	12.8	%
Dividend on Equity (DOE)	0.4	%	0.6	%

10. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
Japan Business Unit						
Lixiana	edoxaban	anticoagulant	2011	Daiichi Sankyo		
Tarlige	mirogabalin	pain treatment	2019	Daiichi Sankyo		
Pralia	denosumab	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	2013	Amgen		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
Tenelia	teneligliptin	type 2 diabetes mellitus treatment	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Vimpat	lacosamide	anti-epileptic agent	2016	UCB	UCB	Co-promotion (DS: Sales)
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Canalia	teneligliptin / canagliflozin	type 2 diabetes mellitus treatment	2017	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	anti-inflammatory analgesic	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Enhertu	trastuzumab deruxtecan	anti-cancer agent (HER2-directed antibody drug conjugate)	2020	Daiichi Sankyo		
Emgality	galcanezumab-gnlm	Prophylaxis of migraine attacks	2021	Eli Lilly Japan	Eli Lilly Japan	Co-promotion (DS: Sales)
Oncology Business Unit						
Enhertu	trastuzumab deruxtecan	anti-cancer agent (HER2-directed antibody drug conjugate)	2020	Daiichi Sankyo	AstraZeneca	Co-promotion (DS: Sales)
Turalio	pexidartinib	anti-cancer agent	2019	Daiichi Sankyo		
American Regent Unit						
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	CSL Vifor	Daiichi Sankyo, Inc.	Promotion (Daiichi Sankyo, Inc.)
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	CSL Vifor	Fresenius	Co-marketing
EU Specialty Business Unit						
Lixiana	edoxaban	anticoagulant	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing
Nilemdo/Nustendi	bempedoic acid, bempedoic acid / ezetimibe	cholesterol-lowering agent	2020	Esperion		
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive agent	2005	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			

<11. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2022	FY2022	FY2022	FY2022	FY2022		FY2023	FY2023	FY2023	FY2023	FY2023			
	Q1	Q2	Q3	Q4	to revenue	Results	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)
	Results	Results	Results	Results			Results	Results	Results	Results				
Revenue	280.3	327.5	340.5	330.2	100.0%	1,278.5	350.8	375.5	446.9	428.4	100.0%	1,601.7	323.2	+25.3%
Cost of sales	74.7	84.7	98.0	91.7	27.3%	349.1	93.6	94.8	122.0	104.4	25.9%	414.8	65.7	+18.8%
Gross Profit	205.6	242.8	242.5	238.5	72.7%	929.4	257.2	280.8	325.0	324.0	74.1%	1,186.9	257.5	+27.7%
SG&A expenses	96.3	113.4	121.1	139.3	36.8%	470.1	135.6	141.0	157.3	193.4	39.2%	627.3	157.2	+33.4%
R&D expenses	74.9	78.9	87.9	95.0	26.3%	336.7	77.2	88.9	90.8	107.5	22.7%	364.3	27.6	+8.2%
Core Operating Profit	34.4	50.4	33.6	4.3	9.6%	122.6	44.5	50.9	76.9	23.0	12.2%	195.3	72.7	+59.3%
Temporary income	0.0	10.8	0.2	10.9		21.9	0.5	0.2	26.2	0.4		27.3	5.4	
Temporary expenses	-	0.0	2.2	21.7		23.9	0.9	0.0	3.6	6.4		10.9	-13.0	
Operating Profit	34.4	61.2	31.6	-6.6	9.4%	120.6	44.0	51.0	99.5	17.0	13.2%	211.6	91.0	+75.5%
Financial income/expenses	-4.9	0.7	4.7	5.9		6.3	8.1	-1.1	-1.8	20.3		25.5	19.2	
Share of profit or loss of investments accounted for using the equity method	-0.0	-0.0	-0.0	0.1		-0.0	0.0	0.0	0.0	0.1		0.2	0.2	
Profit before tax	29.4	61.8	36.2	-0.6	9.9%	126.9	52.1	50.0	97.7	37.4	14.8%	237.2	110.4	+87.0%
Income taxes	10.6	22.4	7.8	-23.1		17.7	-4.9	10.0	30.7	0.5		36.2	18.6	
Profit for the year	18.9	39.5	28.4	22.5	8.5%	109.2	57.0	40.0	67.1	36.9	12.6%	201.0	91.8	+84.1%
Profit attributable to owners of the Company	18.9	39.5	28.4	22.5	8.5%	109.2	57.0	40.0	66.6	37.2	12.5%	200.7	91.5	+83.8%
Tax rate	35.9%	36.2%	21.5%	-		13.9%	-9.4%	20.0%	31.4%	1.3%		15.3%		
Overseas sales ratio	55.4%	58.1%	55.8%	63.4%		58.3%	60.9%	60.0%	57.8%	71.0%		62.5%		
<u>Currency Rate (YTD Average)</u>														
USD/JPY	129.57	138.38	141.64	132.32		135.48	137.37	144.63	147.89	148.60		144.62		
EUR/JPY	138.10	139.34	144.35	142.07		140.97	149.46	157.29	159.10	161.30		156.79		

2. Revenue of Global Products (1)	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2022	FY2023 Q1	FY2023 Q2	FY2023 Q3	FY2023 Q4	FY2023
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
Trastuzumab deruxtecan	37.4	64.4	65.8	90.7	258.4	86.6	96.5	111.4	154.8	449.2
Product sales	31.3	48.2	60.2	67.8	207.5	81.7	91.6	102.6	119.9	395.9
Enhertu(JPN)	2.4	2.8	3.3	3.2	11.7	4.4	6.0	7.3	6.2	23.9
Enhertu (US)	20.0	35.3	44.5	44.8	144.6	51.6	54.3	57.0	62.7	225.5
Enhertu (EU)	6.7	7.0	8.6	14.8	37.1	17.8	21.4	25.5	37.2	101.9
Enhertu (ASCA: Asia, South and Central America)	2.2	3.2	3.8	5.0	14.2	8.0	9.9	12.8	13.8	44.6
Upfront payment	2.5	2.5	2.5	2.5	9.8	2.5	2.5	2.6	2.6	10.1
Regulatory milestone payment	3.4	13.5	2.9	7.0	26.7	2.1	2.1	5.8	2.4	12.4
US HER2+ Breast Cancer 3L	0.2	0.2	0.2	0.2	0.9	0.2	0.2	0.2	0.2	0.9
EU HER2+ Breast Cancer 3L	0.1	0.1	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.5
US HER2+ Gastric Cancer 2L/3L	0.2	0.2	0.2	0.2	0.8	0.2	0.2	0.2	0.2	0.8
US HER2+ Breast Cancer 2L	2.8	0.2	0.2	0.2	3.5	0.2	0.2	0.2	0.2	0.9
EU HER2+ Breast Cancer 2L	-	2.3	0.2	0.2	2.7	0.2	0.2	0.2	0.2	0.7
US HER2-low Breast Cancer (post chemo)	-	6.4	0.5	0.5	7.3	0.5	0.5	0.5	0.5	1.9
EU HER2-low Breast Cancer (post chemo)	-	-	-	5.2	5.2	0.3	0.3	0.4	0.3	1.3
EU HER2+ Gastric Cancer 2L	-	-	1.2	0.1	1.3	0.1	0.1	0.1	0.1	0.3
US HER2 Mutant NSCLC 2L	-	4.0	0.3	0.3	4.6	0.3	0.3	0.3	0.3	1.2
EU HER2 Mutant NSCLC 2L	-	-	-	-	-	-	-	3.6	0.2	3.8
QUID related payment	0.3	0.3	0.3	0.3	1.1	0.3	0.3	0.3	0.3	1.2
Sales milestone payment	-	-	-	13.2	13.2	-	-	-	29.6	29.6
Datopotamab deruxtecan	1.5	2.4	1.6	1.6	7.1	1.6	1.6	1.6	1.6	6.4
Upfront payment	1.5	2.4	1.6	1.6	7.1	1.6	1.6	1.6	1.6	6.4

2. Revenue of Global Products (2)	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2022	FY2023 Q1	FY2023 Q2	FY2023 Q3	FY2023 Q4	FY2023
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
Patritumab deruxtecan	-	-	-	-	-	-	-	1.6	2.0	3.5
Upfront payment	-	-	-	-	-	-	-	1.6	2.0	3.5
Ifinatamab deruxtecan (DS-7300)	-	-	-	-	-	-	-	2.9	3.7	6.6
Upfront payment	-	-	-	-	-	-	-	2.9	3.7	6.6
Raludotatug deruxtecan (DS-6000)	-	-	-	-	-	-	-	1.2	1.5	2.8
Upfront payment	-	-	-	-	-	-	-	1.2	1.5	2.8
Edoxaban	58.9	58.4	65.9	60.8	244.0	66.0	71.7	78.5	71.6	287.7
Lixiana (JPN)	25.1	25.6	28.8	25.6	105.1	27.9	29.3	32.4	26.1	115.6
Savaysa (US)	0.6	0.9	0.5	1.1	3.0	0.5	1.1	0.5	0.4	2.4
Lixiana (EU)	28.6	27.2	32.0	29.3	117.1	32.3	35.6	39.4	38.9	146.2
Edoxaban (ASCA* etc.)	4.6	4.7	4.7	4.7	18.7	5.3	5.8	6.2	6.2	23.5

*Asia, South and Central America

3. Revenue by Business Units and Products (1)	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2022	FY2023 Q1	FY2023 Q2	FY2023 Q3	FY2023 Q4	FY2023
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
Japan Business Unit	109.0	116.0	131.3	101.5	457.9	119.0	127.8	165.5	106.6	518.9
Lixiana	25.1	25.6	28.8	25.6	105.1	27.9	29.3	32.4	26.1	115.6
Pralia	9.9	9.4	11.1	9.8	40.2	10.7	10.4	12.2	9.5	42.8
Tarlige	8.9	9.4	10.8	9.4	38.5	11.7	11.0	12.6	10.3	45.7
Vimpat	5.3	5.3	6.1	5.2	21.9	6.4	6.3	7.2	5.8	25.7
Ranmark	4.9	5.1	5.5	4.8	20.4	5.0	5.3	5.6	4.5	20.4
Tenelia	5.6	5.4	6.0	4.9	21.9	5.3	5.1	5.7	4.3	20.5
Enhertu	2.4	2.8	3.3	3.2	11.7	4.4	6.0	7.3	6.2	23.9
Efient	4.9	5.0	5.8	5.2	20.9	6.1	6.3	7.3	5.9	25.6
Canalia	4.1	4.0	4.4	3.8	16.3	4.1	4.0	4.3	3.4	15.9
Loxonin	4.6	4.8	5.3	3.8	18.5	4.0	4.0	4.5	3.1	15.5
Emgality	1.4	1.6	1.7	1.5	6.3	1.7	1.8	2.1	1.9	7.6
Daiichi Sankyo Espha products	21.0	20.9	24.3	19.9	86.0	20.6	20.6	23.7	18.1	83.0
Vaccines business	0.5	8.1	7.5	-2.7	13.4	0.7	7.5	20.0	-0.5	27.7
Daiichi Sankyo Healthcare Unit	15.3	18.4	21.2	15.6	70.3	17.1	20.3	22.5	16.0	76.0

3. Revenue by Business Units and Products (2)	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2022	FY2023 Q1	FY2023 Q2	FY2023 Q3	FY2023 Q4	FY2023
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
Oncology Business Unit	27.5	43.2	54.0	60.7	185.4	70.6	78.2	84.1	101.7	334.6
Enhertu	26.7	42.3	53.1	59.6	181.6	69.4	75.7	82.4	99.9	327.4
Enhertu (US)	20.0	35.3	44.5	44.8	144.6	51.6	54.3	57.0	62.7	225.5
Enhertu (EU)	6.7	7.0	8.6	14.8	37.1	17.8	21.4	25.5	37.2	101.9
Turalio	0.8	0.9	0.9	1.1	3.8	1.2	1.4	1.5	1.2	5.3
American Regent Unit	47.0	47.1	49.4	43.8	187.4	50.7	48.0	53.3	51.4	203.4
Injectafer	14.1	13.3	14.4	12.1	54.0	13.2	12.5	12.3	12.0	50.1
Venofer	12.4	12.6	13.1	13.1	51.3	15.8	13.3	16.1	15.7	60.9
GE injectables	17.6	18.8	19.2	16.0	71.6	18.3	19.0	21.8	21.9	81.0
EU Specialty Business Unit	37.1	34.7	40.7	37.9	150.4	41.5	44.9	51.2	51.6	189.2
Lixiana	28.6	27.2	32.0	29.3	117.1	32.3	35.6	39.4	38.9	146.2
Nilemdo/Nustendi	1.3	1.5	2.1	2.2	7.1	3.0	3.8	5.2	6.4	18.4
Olmesartan	5.4	4.4	5.0	5.2	20.0	4.7	4.5	5.3	5.1	19.6
ASCA Business Unit	31.9	37.9	36.6	36.3	142.8	39.5	43.6	48.7	52.3	184.1
Daiichi Sankyo China	13.3	16.9	14.4	13.6	58.3	15.5	15.2	19.0	20.7	70.5
Daiichi Sankyo Korea	6.1	6.2	6.3	6.8	25.6	6.3	8.3	7.3	7.3	29.2
Daiichi Sankyo Brasil Farmacêutica	4.8	7.4	7.8	7.8	27.8	8.9	10.0	11.3	11.8	42.0
Daiichi Sankyo Taiwan	3.1	3.3	3.5	3.4	13.3	4.0	3.9	4.1	4.1	16.0
Daiichi Sankyo Thailand	0.6	0.7	0.8	0.8	2.9	0.8	0.8	0.9	0.9	3.5
Daiichi Sankyo Hong Kong	0.6	0.9	0.9	1.0	3.5	1.1	0.5	0.6	0.6	2.9

3. Revenue by Business Units and Products (3)	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2022	FY2023 Q1	FY2023 Q2	FY2023 Q3	FY2023 Q4	FY2023
[Reference] Revenue in Local Currency	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
USD Mn										
Oncology Business Unit	212	315	386	455	1,369	514	541	570	688	2,314
Enhertu	206	309	379	447	1,341	505	524	559	676	2,264
Enhertu (US)	155	258	318	336	1,067	375	375	385	423	1,560
Enhertu (EU)	52	50	61	110	274	130	149	173	253	704
Turalio	6	7	7	9	28	9	9	10	8	37
USD Mn										
American Regent Unit	363	340	349	332	1,383	369	331	361	346	1,407
Injectafer	109	96	102	92	398	96	86	83	81	346
Venofer	96	91	93	99	379	115	92	109	106	421
GE injectables	136	136	136	121	529	133	131	148	148	560
EUR Mn										
EU Specialty Business Unit	269	249	282	267	1,067	278	286	323	320	1,207
Lixiana	207	195	222	207	831	216	226	249	241	933
Nilemdo/Nustendi	10	11	14	15	50	20	24	33	40	118
Olmesartan	39	32	35	37	142	32	28	33	31	125

<12. Historical Data>

1. Revenue of Global Products

	FY2018	FY2019	FY2020	FY2021	FY2022
JPY Bn	Results	Results	Results	Results	Results
Trastuzumab deruxtecan	0.1	14.0	43.5	80.8	258.4
Product sales	-	3.2	30.1	65.4	207.5
Enhertu (JPN)	-	-	4.4	9.6	11.7
Enhertu (US)	-	3.2	25.7	45.4	144.6
Enhertu (EU)	-	-	0.0	9.0	37.1
Enhertu (ASCA: Asia, South and Central America)	-	-	-	1.4	14.2
Upfront payment	0.1	9.8	9.8	9.8	9.8
Regulatory milestone payment	-	0.9	3.5	2.2	26.7
US HER2+ Breast Cancer 3L	-	0.9	0.9	0.9	0.9
EU HER2+ Breast Cancer 3L	-	-	1.0	0.5	0.5
US HER2+ Gastric Cancer 2L/3L	-	-	1.6	0.8	0.8
US HER2+ Breast Cancer 2L	-	-	-	-	3.5
EU HER2+ Breast Cancer 2L	-	-	-	-	2.7
US HER2-low Breast Cancer (post chemo)	-	-	-	-	7.3
EU HER2-low Breast Cancer (post chemo)	-	-	-	-	5.2
EU HER2+ Gastric Cancer 2L	-	-	-	-	1.3
US HER2 Mutant NSCLC 2L	-	-	-	-	4.6
EU HER2 Mutant NSCLC 2L	-	-	-	-	-
QUID related payment	-	-	-	3.4	1.1
Sales milestone payment	-	-	-	-	13.2
Datopotamab deruxtecan	-	-	3.9	6.1	7.1
Upfront payment	-	-	3.9	6.1	7.1
Edoxaban	117.7	154.0	165.9	205.6	244.0
Lixiana (JPN)	64.9	83.0	77.4	92.5	105.1
Savaysa (US)	2.3	2.6	3.0	1.9	3.0
Lixiana (EU)	45.8	61.7	76.7	96.9	117.1
Other subsidiaries	4.7	6.8	8.9	14.3	18.7

2. Revenue by Business Units and Products (1)

	FY2018	FY2019	FY2020	FY2021	FY2022
JPY Bn	Results	Results	Results	Results	Results
Japan Business Unit	523.3	533.5	489.1	489.5	457.9
Lixiana	64.9	83.0	77.4	92.5	105.1
Pralia	27.4	30.9	34.6	37.9	40.2
Tarlige	-	8.0	20.6	30.1	38.5
Vimpat	6.6	11.2	14.5	18.3	21.9
Ranmark	16.4	17.9	19.3	20.4	20.4
Tenelia	25.3	24.7	24.2	23.7	21.9
Enhertu	-	-	4.4	9.6	11.7
Efient	13.9	14.0	14.1	16.7	20.9
Canalia	9.2	12.8	15.4	16.8	16.3
Loxonin	30.5	28.3	24.2	22.2	18.5
Emgality	-	-	-	4.6	6.3
Inavir	18.2	19.3	3.6	1.3	1.1
Daiichi Sankyo Espha products	55.5	60.5	71.4	82.8	86.0
Vaccines business	41.5	35.6	18.5	14.8	13.4
Daiichi Sankyo Healthcare Unit	66.4	68.5	67.2	64.7	70.3

2. Revenue by Business Units and Products (2)

	FY2018	FY2019	FY2020	FY2021	FY2022
JPY Bn	Results	Results	Results	Results	Results
Oncology Business Unit	36.3	32.1	47.4	69.6	185.4
Enhertu	-	3.2	25.7	54.4	181.6
Enhertu (US)	-	3.2	25.7	45.4	144.6
Enhertu (EU)	-	-	0.0	9.0	37.1
Turalio	-	-	1.8	2.8	3.8
American Regent Unit	117.8	130.8	121.7	149.5	187.4
Injectafer	44.2	51.8	44.1	53.1	54.0
Venofer	28.9	31.0	28.8	33.8	51.3
EU Specialty Business Unit	88.6	95.5	111.7	128.2	150.4
Lixiana	45.8	61.7	76.7	96.9	117.1
Nilemdo/Nustendi	-	-	0.6	3.1	7.1
Olmesartan	27.4	24.6	21.5	20.3	20.0
ASCA Business Unit	87.7	98.3	99.7	114.1	142.8
Daiichi Sankyo China	38.5	46.0	45.6	53.3	58.3
Daiichi Sankyo Korea	15.7	17.2	19.6	23.2	25.6
Daiichi Sankyo Brasil Farmacêutica	10.0	11.5	10.5	13.7	27.8
Daiichi Sankyo Taiwan	7.1	7.6	8.3	10.0	13.3
Daiichi Sankyo Thailand	3.3	3.3	2.3	2.2	2.9
Daiichi Sankyo Hong Kong	-	-	0.7	1.7	3.5

2. Revenue by Business Units and Products (3)**[Reference] Revenue in Local Currency**

	FY2018	FY2019	FY2020	FY2021	FY2022
	Results	Results	Results	Results	Results
USD Mn					
Oncology Business Unit	327	295	447	619	1,369
Enhertu	-	30	243	484	1,341
Enhertu (US)	-	30	243	404	1,067
Enhertu (EU)	-	-	0	80	274
Turalio	-	-	17	25	28
USD Mn					
American Regent Unit	1,062	1,204	1,148	1,330	1,383
Injectafer	399	477	416	472	398
Venofer	261	285	272	300	379
EUR Mn					
EU Specialty Business Unit	690	789	903	982	1,067
Lixiana	357	509	620	742	831
Nilemdo/Nustendi	-	-	5	24	50
Olmesartan	213	203	174	155	142

13. Major R&D Pipeline (Innovative Pharmaceuticals)

As of Apr 2024

◆ Explanation of Description

Generic name/Project Code Number (mechanism of action)

Detail on its mechanism

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
<ul style="list-style-type: none"> • Study phase • Study name (if applicable) • CTG registration number • JapicCTI/jRCT registration number • Partner (if applicable) 	Patients and target indications for the study	Target sample size	Study design schematic (randomization or not, blinding or open label, control arm, etc)	<ul style="list-style-type: none"> • Primary and secondary endpoints are listed • Safety measures are summarized as "safety" • Pharmacokinetic indices are summarized as "PK" 	Study locations	<ul style="list-style-type: none"> • Study initiation • TLR • Regulatory filing • Status of application

◆ List of Abbreviations

ADA: anti-drug antibody, ADC: antibody drug conjugate, AGA: actionable genomic alterations, AML: acute myeloid leukemia, BMFI: brain metastases-free interval, BMS: Bristol Myers Squibb, BOR: best overall response, BTC: biliary tract cancer, CBR: clinical benefit rate, CR: complete remission, CRL: complete response letter, DCR: disease control rate, DDFS: distant disease-free survival, DFS: disease-free survival, DOR: duration of response, DRFI: distant recurrence-free interval, EFS: event-free survival, eGFR: estimated glomerular filtration rate, FPD: first patient dosed, FSD: first subject dosed, GMFR: geometric mean fold rise, GMT: geometric mean titer, HCC: hepatocellular carcinoma, IA: interim analysis, IDFS: invasive disease-free survival, MLFS: morphologic leukemia-free state, MRK: Merck & Co., Inc., Rahway, NJ, USA, NSCLC: non small cell lung cancer, ORR: overall response rate/objective response rate, OS: overall survival, PA: primary analysis, pCR: pathological complete response, PDAC: Pancreatic Ductal Adenocarcinoma, PFS: progression-free survival, PK: pharmacokinetics, PLD: pegylated liposomal doxorubicin, PR: partial remission, PRO: patient reported outcome, SCCHN: squamous cell carcinomas of the head and neck, SCLC: small cell lung cancer, SCR: seroconversion rate, TLR: top line results, TNBC: triple negative breast cancer, TTD: Time to deterioration, TTNT: Time to next treatment, TTR: time to response, UACR: urine albumin-creatinine ratio

◆ 5DXd ADCs

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Brand name: ENHERTU (JP/US/EU/China)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 (registrational) DESTINY-Breast01 NCT03248492 JapicCTI-173693 AstraZeneca	HER2 positive breast cancer, 3L	253	Randomized, open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, PFS, OS, etc.	JP/US/EU /Asia	FPD: Oct 2017 TLR: May 2019 Jan 2020: Launched (US) May 2020: Launched (JP) Feb 2021: Launched (EU)
Phase 3 DESTINY-Breast02 NCT03523585 JapicCTI-184017 AstraZeneca	HER2 positive breast cancer, 3L	608	Randomized, open label, active controlled •DS-8201 •Physician's choice (trastuzumab + capecitabine or lapatinib + capecitabine)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS, etc.	JP/US/EU /Asia	FPD: Sep 2018 TLR: Aug 2022
Phase 3 DESTINY-Breast03 NCT03529110 JapicCTI-183976 AstraZeneca	HER2 positive breast cancer, 2L	524	Randomized, open label, active controlled •DS-8201 •T-DM1	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS, etc.	JP/US/EU /Asia	FPD: Aug 2018 TLR: Aug 2021 May 2022: Approved (US) Jul 2022: Approved (EU) Nov 2022: Approved (JP) Feb 2023: Approved (CN) Aug 2021: Real Time Oncology Review Designation (US) Sep 2021: Breakthrough Therapy Designation (US)

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 DESTINY-Breast04 NCT03734029 JapicCTI-184223 AstraZeneca	HER2 low breast cancer, post chemotherapy	557	Randomized, open label, active controlled •DS-8201 •Physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, etc.	JP/US/EU /Asia	FPD: Dec 2018 TLR: Feb 2022 Aug 2022: Approved (US) Jan 2023: Approved (EU) Mar 2023: Approved (JP) Jul 2023: Approved (CN) Feb 2022: Real Time Oncology Review Designation (US) Apr 2022: Breakthrough Therapy Designation (US) Aug 2022: Priority Review Designation (JP)
Phase 3 DESTINY-Breast05 NCT04622319 jRCT2061200033 AstraZeneca	HER2 positive breast cancer with residual invasive disease following neoadjuvant therapy, adjuvant therapy	1,600	Randomized, open label, active controlled •DS-8201 •T-DM1	Primary endpoint: IDFS Secondary endpoint: DFS, OS, DRFI, BMFI, safety, PK, etc.	JP/US/EU /Asia	FPD: Dec 2020
Phase3 DESTINY-Breast06 NCT04494425 jRCT2061200028 AstraZeneca	HER2 low/HR positive breast cancer, chemotherapy naïve	866	Randomized, open label, active controlled •DS-8201 •Physician's choice (capecitabine, paclitaxel or nab-paclitaxel)	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, safety, etc.	JP/US/EU /Asia	FPD: Aug 2020 TLR anticipated: FY2024 H1
Phase1b/2 DESTINY-Breast07 NCT04538742 AstraZeneca	HER2 positive breast cancer Part 1: 2L or later Part 2: 1L	244	Open label, two-part (dose escalation, dose expansion) •DS-8201 + durvalumab •DS-8201 + pertuzumab •DS-8201 + paclitaxel •DS-8201 + durvalumab + paclitaxel •DS-8201 + tucatinib •DS-8201	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: Jan 2021

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase1b DESTINY-Breast08 NCT04556773 AstraZeneca	HER2 low breast cancer chemotherapy naïve, post chemotherapy	139	Open label, two-part (dose escalation, dose expansion) •DS-8201 + capecitabine •DS-8201 + durvalumab + paclitaxel •DS-8201 + capivasertib (AZD5363) •DS-8201 + anastrozole •DS-8201 + fulvestrant	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: Jan 2021
Phase3 DESTINY-Breast09 NCT04784715 jRCT2031210130 AstraZeneca	HER2 positive breast cancer, 1L	1,156	Randomized, open label, active controlled •DS-8201 •DS-8201 + pertuzumab •Taxane + trastuzumab + pertuzumab	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, PK, safety, etc.	JP/US/EU /Asia	FPD: Jun 2021
Phase3 DESTINY-Breast11 NCT05113251 jRCT2041210097 AstraZeneca	HER2 positive breast cancer, neoadjuvant	900	Randomized, open label, active controlled •DS-8201 •DS-8201, followed by paclitaxel + trastuzumab + pertuzumab •doxorubicin + cyclophosphamide, followed by paclitaxel + trastuzumab + pertuzumab	Primary endpoint: pCR Secondary endpoint: EFS, IDFS, OS	JP/US/EU /Asia	FPD: Nov 2021 TLR anticipated: FY2024 H2
Phase 1b/2 BEGONIA NCT03742102 AstraZeneca	TNBC	240	Non-randomized, open label, combination with durvalumab •DS-8201 + durvalumab * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: May 2020
Phase 2 (registrational) DESTINY-Gastric01 NCT03329690 JapicCTI-173727 AstraZeneca	HER2 positive, gastric or gastroesophageal junction adenocarcinoma, 3L	233	Randomized, open label, active controlled •DS-8201 •Physician's choice (irinotecan or paclitaxel)	Primary endpoint: ORR Secondary endpoint: PFS, OS, DOR, DCR, TTF, ORR, PK	JP/Asia	FPD: Nov 2017 TLR: Jan 2020 Sep 2020: Approved (JP) Jan 2021: Approved (US) Dec 2022: Approved (EU) Mar 2018: SAKIGAKE Designation (JP) May 2020: Breakthrough Therapy Designation (US) May 2020: Orphan Drug Designation (US)

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-Gastric02 NCT04014075 AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 2L	79	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: PFS, ORR, OS, DOR	US/EU	FPD: Dec 2019 TLR: Jun 2021 Dec 2022: Approved (EU)
Phase 1b/2 DESTINY-Gastric03 NCT04379596 jRCT2031200203 AstraZeneca	HER2 positive gastric or gastroesophageal junction and esophageal adenocarcinoma Part 1: 2L Part 2: 1L Part 3: 1L Part 4: 1L	413	Randomized, open label Part 1 •DS-8201 + fluorouracil •DS-8201 + capecitabine •DS-8201 + durvalumab •DS-8201 + oxaliplatin + fluorouracil •DS-8201 + capecitabine + oxaliplatin •DS-8201 + durvalumab + fluorouracil •DS-8201 + capecitabine + durvalumab Part 2 •DS-8201 •DS-8201 + oxaliplatin + fluorouracil or capecitabine •DS-8201 + pembrolizumab + fluorouracil or capecitabine •DS-8201 + pembrolizumab •Trastuzumab + fluorouracil or capecitabine + cisplatin or oxaliplatin Part 3 •DS-8201 + volrustomig (MEDI5752) + fluorouracil or capecitabine Part 4 •DS-8201 + rilvegostomig (AZD2936) + fluorouracil or capecitabine	Primary endpoint: Part 1: safety Part 2,3,4: ORR Secondary endpoint: ORR, safety, DOR, DCR, PFS, OS, PK, ADA	JP/US/EU /Asia	FPD: Jun 2020

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 DESTINY-Gastric04 NCT04704934 jRCT2031200369 AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 2L	490	Randomized, open label •DS-8201 •Ramucirumab + paclitaxel	Primary endpoint: OS Secondary endpoint: PFS, ORR, DOR, DCR, safety, PK, ADA, etc.	JP/EU /Asia	FPD: Jun 2021
Phase 2 DESTINY-Gastric06 NCT04989816 AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 3L	95	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, PFS, DCR, DOR, OS, Tumor size change, PK, ADA	China	FPD: Sep 2021 TLR: Jul 2023 Dec 2023: Filing accepted (CN) Nov 2023: Priority Review Designation (CN)
Phase 2 DESTINY-Lung01 NCT03505710 JapicCTI-183916 AstraZeneca	HER2 overexpressing or HER2 mutant NSCLC, 2L or later	181	Non-randomized, open label HER2 overexpressing NSCLC •DS-8201 6.4mg/kg •DS-8201 5.4mg/kg HER2 mutant NSCLC •DS-8201 6.4mg/kg	Primary endpoint: ORR Secondary endpoint: ORR, DOR, PFS, OS, DCR	JP/US/EU	FPD: May 2018 TLR: Jun 2021 HER2 mutant NSCLC Aug 2022: Approval (US) (with consideration of the interim analysis data of DESTINY-Lung02) May 2020: Breakthrough Therapy Designation (US) Sep 2022: Orphan Drug Designation (JP) HER2 overexpressing NSCLC Apr 2024: Approved as part of HER2 positive tumor-agnostic (US) Jan 2024: Priority Review Designation (US)
Phase 2 DESTINY-Lung02 NCT04644237 jRCT2061200038 AstraZeneca	HER2 mutant NSCLC, 2L or later	152	Randomized, double blind •DS-8201: 6.4mg/kg •DS-8201: 5.4mg/kg	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, PFS, OS, safety	JP/US/EU /Asia	FPD: Mar 2021 TLR (IA): May 2022 TLR (PA): Feb 2023 Aug 2022: Approval (US) Aug 2023: Approval (JP) Oct 2023: Approval (EU)

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b DESTINY-Lung03 NCT04686305 AstraZeneca	HER2 positive NSCLC, 1L	168	Non-randomized, three-part (safety run-in, dose escalation, dose expansion) •DS-8201 + durvalumab + cisplatin •DS-8201 + durvalumab + carboplatin •DS-8201 + durvalumab + pemetrexed •DS-8201 + durvalumab •DS-8201 + volrustomig (MEDI5752) •DS-8201 + volrustomig (MEDI5752) + carboplatin	Primary endpoint: safety Secondary endpoint: ORR, DOR, DCR, PFS, OS, PK, etc.	US/EU /Asia	FPD: Nov 2021
Phase 3 DESTINY-Lung04 NCT05048797 jRCT2011210058 AstraZeneca	NSCLC with HER2 exon 19 or exon 20 mutation, 1L	450	Randomized, open label •DS-8201 •pemetrexed + pembrolizumab + cisplatin or carboplatin	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, safety, PK, etc.	JP/US/EU /Asia	FPD: Dec 2021
Phase 2 DESTINY-Lung05 NCT05246514 AstraZeneca	NSCLC with HER2 exon 19 or exon 20 mutation, 2L or later	72	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, PFS, OS, PK, ADA, safety	China	FPD: Aug 2022 TLR: Nov 2023 Mar 2024: Filing accepted (CN) Mar 2024: Priority Review Designation (CN)
Phase 2 HUDSON NCT03334617 AstraZeneca	NSCLC, 2L or later	531	Non-randomized, open label, combination with durvalumab •DS-8201 + durvalumab * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: ORR Secondary endpoint: DCR, best percentage change in tumor size, DOR, PFS, OS	US/EU /Asia	FPD: Jun 2020 TLR: Aug 2022

Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-CRC02 NCT04744831 jRCT2051200124 AstraZeneca	HER2 overexpressing colorectal cancer, 3L	122	Randomized, double blind •DS-8201: 6.4mg/kg •DS-8201: 5.4mg/kg	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, OS, PK, PRO, safety, etc.	JP/US/EU /Asia	FPD: Mar 2021 TLR: Jan 2023 Apr 2024: Approved as part of HER2 positive tumor-agnostic (US) Breakthrough Therapy Designation (US) Jan 2024: Priority Review Designation (US)
Phase 2 DESTINY-PanTumor02 NCT04482309 AstraZeneca	HER2 expressing tumors (bladder cancer, BTC, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, rare tumors)	468	Non-randomized •DS-8201	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, OS, safety, PK, ADA	US/EU /Asia	FPD: Oct 2020 TLR: Jul 2023 Apr 2024: Approved (US) Sep 2023: Breakthrough Therapy Designation (US) Jan 2024: Priority Review Designation (US)
Phase 2 DESTINY-PanTumor03 NCT06271837 AstraZeneca	HER2 overexpressing tumors	50	Non-randomized, open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR by investigator, DOR, DCR, BOR, PFS, OS, safety, PK, ADA	China	FPD: Feb 2024
Phase 1 NCT04042701 MRK	HER2 positive/low breast cancer HER2 expressing/HER2 mutant NSCLC	115	Non-randomized, open label, combination with pembrolizumab •DS-8201 + pembrolizumab	Primary endpoint: safety, ORR Secondary endpoint: DOR, DCR, PFS, TTR, OS	US/EU	FPD: Apr 2020
Phase 1/2a PETRA NCT04644068 jRCT2031210609 AstraZeneca	Solid tumors	804	Non-randomized, open label, combination with AZD5305 •DS-8201 + saruparib (AZD5305)	Primary endpoint: safety Secondary endpoint: tumor size change, ORR, DOR, PFS, TTR, PK, ADA, etc	JP/US/EU /Asia	FPD: Sep 2022

Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting TROP2 (Research collaboration with Sapporo Medical University). TROP2 is an antigen highly expressed on the cell membrane of cancer cells, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 4.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 TROPION- PanTumor01 NCT03401385 JapicCTI-173812 AstraZeneca	NSCLC TNBC HR positive, HER2 low or negative breast cancer SCLC Transitional cell carcinoma of the urothelium HER2 negative gastroesophageal cancer Esophageal cancer Prostate cancer, etc.	890	Open label, two-part (dose escalation, dose expansion) •DS-1062	Primary endpoint: safety Secondary endpoint: PK, ADA	JP/US	FPD: Feb 2018
Phase 1/2 TROPION- PanTumor02 NCT05460273 AstraZeneca	NSCLC TNBC	119	Open label •DS-1062	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, BOR, TTR, PFS, OS, safety, PK, etc.	China	FPD: Jul 2022
Phase 2 TROPION- PanTumor03 NCT05489211 jRCT2031220404 AstraZeneca	Endometrial cancer Gastric cancer Castration-resistant prostate cancer Ovarian cancer Colorectal cancer Urothelial cancer BTC	670	Open label •DS-1062 •DS-1062 in combination with approved or novel anticancer agents	Primary endpoint: ORR, safety Secondary endpoint: PFS, DOR, DCR, best percentage change in tumor size, ADA, PK, etc.	JP/US/EU /Asia	FPD: Sep 2022
Phase 3 TROPION-Lung01 NCT04656652 jRCT2071200104 AstraZeneca	NSCLC, 2L/3L	590	Randomized, open label, active controled •DS-1062 •Docetaxel	Primary endpoint: PFS, OS Secondary endpoint: PFS, ORR, DOR, TTR, DCR, safety, PK, ADA	JP/US/EU /Asia	FPD: Feb 2021 TLR: Jul 2023 Feb 2024: Filing accepted (US) Mar 2024: Filing accepted (EU)

Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 TROPION-Lung02 NCT04526691 jRCT2031200193 MRK AstraZeneca	NSCLC (without AGA) Part 1: 3L or later Part 2: 1L/2L	145	Open label, combination with pembrolizumab, two-part (dose escalation, dose expansion) •DS-1062 + pembrolizumab ± platinum chemotherapy	Primary endpoint: safety and tolerability Secondary endpoint: ORR, DOR, PFS, OS, PK, ADA	JP/US/EU /Asia	FPD: Oct 2020
Phase 1 TROPION-Lung04 NCT04612751 jRCT2031200449 AstraZeneca	NSCLC (without AGA), 1L/2L	321	Open label, combination with immunotherapy, two-part (dose escalation, dose expansion) •DS-1062 + durvalumab ± carboplatin •DS-1062 + rilvegostomig (AZD2936) ± carboplatin •DS-1062 + volrustomig (MEDI5752) ± carboplatin •DS-1062 + sabestomig (AZD7789)	Primary endpoint: safety and tolerability Secondary endpoint: ORR, DOR, PFS, TTR, OS, PK, ADA, etc.	JP/US/EU	FPD: Mar 2021
Phase 2 TROPION-Lung05 NCT04484142 jRCT2041200097 AstraZeneca	NSCLC (with AGA)	137	Open label •DS-1062	Primary endpoint: ORR Secondary endpoint: DOR, PFS, OS, safety, PK, ADA	JP/US/EU /Asia	FPD: Mar 2021 TLR: Mar 2023
Phase 3 TROPION-Lung07 NCT05555732 jRCT2061220066 MRK AstraZeneca	non-squamous NSCLC (without AGA and PD-L1 <50%), 1L	975	Randomized, open label, active controlled •DS-1062 + pembrolizumab + cisplatin or carboplatin •DS-1062 + pembrolizumab •Pembrolizumab + pemetrexed + cisplatin or carboplatin	Primary endpoint: PFS, OS Secondary endpoint: ORR, PFS, DOR, TTR, DCR, TTD, safety, ADA, etc.	JP/US/EU /Asia	FPD: Jan 2023

Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 TROPION-Lung08 NCT05215340 jRCT2061210074 MRK AstraZeneca	NSCLC (without AGA and PD-L1 \geq 50%, 1L)	740	Randomized, open label, active controlled •DS-1062 + pembrolizumab •Pembrolizumab	Primary endpoint: PFS, OS Secondary endpoint: ORR, PFS, DOR, TTR, DCR, TTD, safety, ADA, etc.	JP/US/EU /Asia	FPD: Mar 2022
Phase 3 TROPION-Lung10 NCT06357533 AstraZeneca	non-squamous NSCLC (without AGA and PD-L1 \geq 50%), 1L	675	•rilvegostomig (AZD2963) •DS-1062+ rilvegostomig (AZD2963) •Pembrolizumab	Primary endpoint: PFS (TROP2 biomarker positive), OS (TROP2 biomarker positive) Secondary endpoint: PFS (ITT), OS (ITT), ORR, DOR, PK, immunogenicity, etc.	JP/US/EU /Asia	FPD planned: FY2024 H1
Phase 3 TROPION-Lung14 NCT06350097 AstraZeneca	EGFR mutated NSCLC, 1L	582	Randomized, open label, active controlled •DS-1062 + osimertinib •Osimertinib	Primary endpoint: PFS Secondary endpoint: OS, CNS PFS, PFS by investigator, ORR, DOR, ADA, etc.	JP/US/EU /Asia	FPD planned: FY2024 H1
Phase 1b/2 BEGONIA NCT03742102 AstraZeneca	TNBC, 1L	240	Non-randomized, open label, combination with durvalumab •DS-1062 + durvalumab •DS-1062 + durvalumab (patients with PD-L1 positive status) * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: safety Secondary endpoint: ORR, PFS, DOR, OS, PK	US/EU /Asia	FPD: May 2021

Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 TROPION-Breast01 NCT05104866 jRCT2031210440 AstraZeneca	HR positive, HER2 low or negative breast cancer, 2L/3L	732	Randomized, open label, active controled •DS-1062 •Physician's choice (capecitabine, gemcitabine, eribulin or vinorelbine)	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, PFS, DCR, PK, ADA, etc	JP/US/EU /Asia	FPD: Nov 2021 TLR: Sep 2023 Mar 2024: Filing accepted (JP, EU, CN) Apr 2024: Filing accepted (US)
Phase 3 TROPION-Breast02 NCT05374512 jRCT2061220029 AstraZeneca	TNBC, PD-1/PD-L1 inhibitor ineligible, 1L	600	Randomized, open label, active controled •DS-1062 •Physician's choice (paclitaxel, nab-paclitaxel, carboplatin, capecitabine, eribulin)	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, PFS, TTD, PK, ADA, safety, etc	JP/US/EU /Asia	FPD: Jun 2022 TLR anticipated: FY2024 H2
Phase 3 TROPION-Breast03 NCT05629585 jRCT2061220087 AstraZeneca	TNBC with residual invasive disease following neoadjuvant therapy, adjuvant therapy	1,075	Randomized, open label, active controled •DS-1062 + durvalumab •DS-1062 •Physician's choice (capecitabine, pembrolizumab, capecitabine + pembrolizumab)	Primary endpoint: IDFS Secondary endpoint: DDFS, OS, IDFS, TTD, fatigue, PK, ADA, safety and tolerability	JP/US/EU /Asia	FPD: Dec 2022
Phase 3 TROPION-Breast04 NCT06112379 jRCT2031230723 AstraZeneca	TNBC, HR low and HER2 negative BC, neoadjuvant with durvalumab and ajuvant with durvalumab ± chemotherapy	1,728	Randomized, open label, active controled •DS-1062 + durvalumab as neoadjuvant, durvalumab ± chemotherapy as adjuvant •pembrolizumab + chemotherapy as neoadjuvant, pembrolizumab ± chemotherapy as adjuvant	Primary endpoint: pCR, EFS Secondary endpoint: OS, DDFS, PROs, PK, ADA, safety	JP/US/EU /Asia	FPD: Nov 2023
Phase 3 TROPION-Breast05 NCT06103864 jRCT2061230102 AstraZeneca	PD-L1 positive TNBC, with or without durvalumab, 1L	625	Randomized, open label, active controled •DS-1062 + durvalumab •DS-1062 •Physician's choice of chemotherapy in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS by investigator assesment, CBR, TTD, etc.	JP/US/EU /Asia	FPD: Nov 2023

Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2a PETRA NCT04644068 jRCT2031210609 AstraZeneca	Solid tumors	804	Non-randomized, open label, combination with AZD5305 •DS-1062 + saruparib (AZD5305)	Primary endpoint: safety Secondary endpoint: tumor size change, ORR, DOR, PFS, TTR, PK, ADA, etc	JP/US/EU /Asia	FPD: Mar 2022
Phase 2 ORCHARD NCT03944772 jRCT2080224686 AstraZeneca	EGFR mutated NSCLC, 2L	248	Non-randomized, open label •DS-1062 + osimertinib * Platform study of osimertinib led by AstraZeneca	Primary endpoint: ORR Secondary endpoint: PFS, DOR, OS, PK, safety, etc.	JP/US/EU /Asia	FPD: Jul 2022
Phase 2 NeoCOAST-2 NCT05061550 AstraZeneca	Resectable, early-stage NSCLC, neoadjuvant	490	Non-randomized, open label •DS-1062 + durvalumab + single agent platinum chemotherapy as neoadjuvant treatment and durvalumab as adjuvant treatment * Platform study of durvalumab led by AstraZeneca	Primary endpoint: pCR, safety Secondary endpoint: EFS, DFS, ORR, OS, etc.	US/EU /Asia	FPD: Aug 2023

Patritumab deruxtecan/U3-1402/HER3-DXd (HER3-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting HER3, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT03260491 JapicCTI-194868 MRK	NSCLC	271	Non-randomized, open label, two-part (dose escalation, dose expansion) •U3-1402	Primary endpoint: safety and tolerability, ORR, PK Secondary endpoint: PK, ADA, ORR, DCR, DOR, TTR, PFS, OS, safety	JP/US/EU /Asia	FPD: Feb 2018
Phase 2 (registrational) HERTHENA-Lung01 NCT04619004 jRCT2031200186 MRK	EGFR mutated NSCLC, 3L	277	Randomized, open label •U3-1402	Primary endpoint: ORR Secondary endpoint: DOR, PFS, ORR, DCR, TTR, OS, safety, etc.	JP/US/EU /Asia	FPD: Feb 2021 TLR: disclosed in Apr 2023 Dec 2023: Filing accepted (US) Dec 2021: Breakthrough Therapy Designation (US) Real Time Oncology Review Designation (US) Dec 2023: Priority Review Designation (US)
Phase 3 HERTHENA-Lung02 NCT05338970 jRCT2021220002 MRK	EGFR mutated NSCLC, 2L	586	Randomized, open label, active controlled •U3-1402 •Platinum-based chemotherapy	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, CBR, DCR, safety, etc.	JP/US/EU /Asia	FPD: Aug 2022 TLR anticipated: FY2024 H2
Phase 1 NCT04676477 jRCT2031200247 AstraZeneca MRK	EGFR mutated NSCLC, 1/2L	280	Non-randomized, open label, two-part (dose escalation, dose expansion) •U3-1402 + Osimertinib	Primary endpoint: safety and tolerability, ORR Secondary endpoint: ORR, DOR, DCR, TTR, PFS, OS, safety, PK, etc.	JP/US /Asia	FPD: Jun 2021

Patritumab deruxtecan/U3-1402/HER3-DXd (HER3-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 HERTHENA- PanTumor01 NCT06172478 jRCT2031230575 MRK	Melanoma, SCCHN, and HER2- negative gastric cancer	120	Non-randomized, open label •U3-1402	Primary endpoint: ORR Secondary endpoint: safety, DOR, CBR, DCR, TTR, PFS, OS, PK, etc.	JP/US/EU /Asia	FPD: Mar 2024

Ifinatamab deruxtecan/DS-7300/I-DXd (B7-H3-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting B7-H3, one of the immunomodulatory molecules belonging to B7 family, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 4.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 IDeate-PanTumor01 NCT04145622 JapicCTI-194992 MRK	Esophageal squamous cell carcinoma, castration-resistant prostate cancer, sq-NSCLC, SCLC, etc.	250	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-7300	Primary endpoint: safety and tolerability, antitumor effect Secondary endpoint: PK, etc.	JP/US	FPD: Oct 2019
Phase 2 IDeate-Lung01 NCT05280470 jRCT2041220019 MRK	Extensive-stage SCLC, 2L or later	180	Randomized, open label •DS-7300 : 8mg/kg •DS-7300 : 12mg/kg	Primary endpoint: ORR Secondary endpoint: safety, PFS, DOR, OS, TTR, ORR, DCR, PK, ADA	JP/US/EU /Asia	FPD: Jun 2022 TLR anticipated: FY2024 H2 Apr 2023: Orphan Drug Designation (US)
Phase 3 in prep IDeate-Lung02 NCT06203210 jRCT2031230631 MRK	Extensive-stage SCLC, 2L or later	468	Randomized, open label, active controlled •DS-7300 : 12mg/kg •Physician's choice (topotecan, amrubicin, lurbinectedin)	Primary endpoint: ORR by BICR, OS Secondary endpoint: ORR by investigator, PFS, DOR, DCR, TTR, safety, ADA, etc.	JP/US/EU /Asia	FPD planned: FY2024 H1

Ifinatamab deruxtecan/DS-7300/I-DXd (B7-H3-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b/2 in prep IDeate-Lung03 NCT06362252 MRK	Extensive-stage SCLC, 1L	149	Randomized, open label, two-part (safety run-in and dose optimization) Part A Cohort 1: maintenance •DS-7300 12mg/kg Cohort 2: induction and maintenance •DS-7300 8mg/kg or 12mg/kg + atezolizumab, carboplatin for induction + atezolizumab for maintenance Part B Cohort 1: randomization after induction by etoposide + atezolizumab + carboplatin •DS-7300 8mg/kg or 12mg/kg + atezolizumab Cohort 2: induction and maintenance •DS-7300 8mg/kg or 12mg/kg + atezolizumab, carboplatin for induction + atezolizumab for maintenance	Primary endpoint: safety Secondary endpoint: PFS, ORR, DOR, DCR, CBR, TTR, OS, PK, etc.	JP/US/EU /Asia	FPD planned: FY2024 H1
Phase 2 in prep NCT06330064 jRCT2031240016 MRK	endometrial, SCCHN, PDAC, CRC, HCC, esophagus, gastroesophageal junction, and stomach, non-squamous NSCLC, urothelial, 2L or later	260	Non-randomized, open label •DS-7300	Primary endpoint: ORR Secondary endpoint: safety, DOR, PFS, DCR, OS, PK, ADA, etc.	JP/US/EU /Asia	FPD planned: FY2024 H1

Raludotatug deruxtecan/DS-6000/R-DXd (CDH6-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting CDH6, one of the cadherin proteins relating to tumor growth and poor prognosis, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04707248 jRCT2031220075 MRK	Renal cell carcinoma, ovarian cancer	140	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-6000	Primary endpoint: safety and tolerability Secondary endpoint: PK, ORR, DOR, DCR, etc.	JP/US	FPD: Jan 2021
Phase 2/3 REJOICE-Ovarian01 NCT06161025 jRCT2031230556 MRK	Platinum-resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer, 2L or later	650	Randomized, open label, two-part (Part A (Phase 2): dose optimization, Part B (Phase 3): comparing efficacy with investigator's choice of chemotherapy) •DS-6000 •Physician's choice (gemcitabine, paclitaxel, topotecan, PLD)	Primary endpoint: ORR by BICR for Part A. PFS, ORR by BICR for Part B Secondary endpoint: ORR by investigator, DOR, PFS (for Part A), DCR, OS, safety, PK, etc.	JP/USEU/ Asia	FPD: Apr 2024

◆ Next Wave (Oncology Late-Stage Pipeline Products)

Quizartinib/AC220 (FLT3 inhibitor)

Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring *FLT3*-ITD mutation is expected.
Brand name: VANFLYTA (JP/US)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 QuANTUM-First NCT02668653 JapicCTI-173667	<i>FLT3</i> -ITD positive AML, 1L	539	Randomized, double-blind, placebo-controlled •Quizartinib + chemotherapy •Placebo + chemotherapy	Primary endpoint: OS Secondary endpoint: EFS, etc.	JP/US/EU /Asia	FPD: Sep 2016 TLR: Nov 2021 May 2023: Approved (JP) Jul 2023: Approved (US) Nov 2023: Approved (EU) Mar 2009: Orphan Drug Designation (US/EU) Sep 2018: Orphan Drug Designation (JP) Fast Track Designation (US) Priority Review Designation (US)

Pexidartinib/PLX3397 (CSF-1/KIT/FLT3 inhibitor)

The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3 specifically. This agent is expected to reduce tumor cell proliferation and expansion of metastases.

Brand name: TURALIO (US)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 NCT04488822	Tenosynovial giant cell tumor	35	Open label •Pexidartinib	Primary endpoint: ORR Secondary endpoint: TVS, ROM, PROMIS, DOR, etc.	Asia	FPD: Sep 2020
Phase 2 NCT04703322 jRCT2041200074	Tenosynovial giant cell tumor	21	Open label •Pexidartinib	Primary endpoint: safety and tolerability, PK, ORR Secondary endpoint: safety, ORR, ROM, PROMIS, DOR, etc.	JP	FPD: Apr 2021

Valemetostat/DS-3201 (EZH1/2 inhibitor)

Inhibitor of histone methylases, EZH1 and EZH2. Some cancer cells grow dependently on these enzymes.

Brand name: EZHARMIA (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 (registrational) NCT04102150 JapicCTI-194964	Adult T-cell leukemia-lymphoma	25	Open label •DS-3201	Primary endpoint: ORR Secondary endpoint: ORR, CR rate, TTR, DOR, PFS, OS, etc.	JP	FPD: Dec 2019 TLR: Jul 2021 Sep 2022: Approved (JP) Nov 2021: Orphan Drug Designation
Phase 2 (registrational) VALENTINE-PTCL01 NCT04703192 jRCT2071200095	Relapsed/refractory peripheral T-cell lymphoma	148	Non-Randomized, open label •DS-3201	Primary endpoint: ORR Secondary endpoint: DOR, CR rate, safety, etc.	JP/US/EU /Asia	FPD: Jun 2021 TLR: Jun 2023 Jan 2024: Filing accepted (JP) Apr 2019: SAKIGAKE Designation (JP) Dec 2021: Orphan Drug Designation (US)
Phase 2 NCT04842877 LYSA	Relapsed/refractory B-cell lymphoma	141	Non-Randomized, open label •DS-3201	Primary endpoint: ORR Secondary endpoint: CR rate, PFS, DOR, TTR, safety, PK	EU	FPD: Jun 2021

Valemetostat/DS-3201 (EZH1/2 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b NCT06244485 jRCT2031230614	HER2-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma, non-squamous NSCLC	140	Non-Randomized, open-label, two-part Part 1: Dose escalation and Part 2: Dose expansion •DS-3201+DS-8201 •DS-3201+DS-1062	Primary endpoint: Part 1: safety Part 2: ORR Secondary endpoint: OS, PFS, DOR, ORR, safety, etc	JP/US	FPD: Feb 2024
Phase 1 NCT02732275 JapicCTI-163173	Non-Hodgkin's lymphoma	100	Open label •DS-3201	Primary endpoint: safety, PK, antitumor effect Secondary endpoint: ORR, DCR, DOR, PFS, etc.	JP/US	FPD: Apr 2016

◆ Next Wave (Oncology Early-Stage Pipeline Products)

DS-1001 (Mutant IDH1 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT03030066 JapicCTI-163479	Glioma	47	Open label •DS-1001	Primary endpoint: tolerability Secondary endpoint: safety, PK, antitumor effect	JP	FPD: Jan 2017
Phase 2 NCT04458272 JapicCTI-205339	Glioma	25	Open label •DS-1001	Primary endpoint: ORR, safety Secondary endpoint: antitumor effect, TTR, DOR, PFS, OS, PK, etc	JP	FPD: Jul 2020 TLR: Sep 2023

DS-1055 (anti-GARP antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04419532 JapicCTI-205292	Solid tumors	40	Non-randomized, open label •DS-1055	Primary endpoint: safety and tolerability Secondary endpoint: PK, ADA, etc.	JP/US	FPD: Oct 2020

DS-9606 (Target undisclosed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05394675	Solid tumors	125	Non-randomized, open label •DS-9606	Primary endpoint: safety and tolerability, ORR Secondary endpoint: PK, DOR, DCR, TTR, PFS, ADA, etc.	US/EU	FPD: Jun 2022

DS-1103 (anti-SIRP α antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05765851	HER2 expressing or mutant solid tumors (dose escalation part), HER2-low BC (dose expansion part)	78	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-1103 + DS-8201	Primary endpoint: safety and tolerability, ORR Secondary endpoint: ORR, DCR, CBR, DOR, PK, ADA, etc.	US/EU	FPD: Jun 2023

DS-3939 (TA-MUC1-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT05875168 jRCT2031230233 Glycotope GmbH	Solid tumors	430	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-3939	Primary endpoint: safety and tolerability, ORR Secondary endpoint: ORR, DCR, DOR, TTR, PFS, OS, PK, ADA, etc.	JP/US	FPD: Sep 2023

DS-1471 (anti-CD147 antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT06074705 jRCT2031230234	Solid tumors	80	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-1471	Primary endpoint: safety and tolerability Secondary endpoint: BOR, ORR, DCR, DOR, TTR, PFS, OS, PK, ADA etc.	JP	FPD: Sep 2023

◆ Next Wave (Specialty Medicines Late-Stage Pipeline Products)

Mirogabalin/DS-5565 ($\alpha_2\delta$ ligands)

The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.

Brand name: TARLIGE (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 NCT04094662	Diabetic peripheral neuropathic pain	393	Randomized, double-blind, placebo-controlled •Mirogabalin •Placebo	Primary endpoint: average daily pain score Secondary endpoint: visual analogue scale, average daily sleep interference score	China	FPD: Sep 2019 Jan 2023: Filing accepted (CN)

Esaxerenone/CS-3150 (MR blocker)

The agent inhibits aldosterone binding to Mineralocorticoid Receptor (MR) which stimulate the sodium absorption into kidney. This agent is expected to exhibit antihypertensive and organ-protective effect.

Brand name: MINNEBRO (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-173695 Exelixis, Inc.	Diabetic nephropathy	400	Randomized, double-blind, placebo-controlled •Esaxerenone •Placebo	Primary endpoint: UACR remission rate Secondary endpoint: change rate in UACR and eGFR, etc.	JP	FPD: Sep 2017 TLR: Jul 2019

◆ Next Wave (Specialty Medicines Early-Stage Pipeline Products)

DS-1211 (TNAP inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 NCT05569252	Pseudoxanthoma elasticum	65	Randomized, double-blind, placebo-controlled •DS-1211	Primary endpoint: safety, pharmacodynamic (PD) dose response Secondary endpoint: PK	US/EU	FPD: Nov 2022 TLR: Apr 2024

DS-7011 (anti-TLR7 antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b/2 NCT05638802	Adult subjects with SLE including cutaneous lupus erythematosus (CLE)	24	Randomized, double-blind, placebo-controlled •DS-7011	Primary endpoint: safety and tolerability Secondary endpoint: PK, efficacy, immunogenicity	US	FPD: Jul 2023

DS-2325 (KLK5 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1b/2 NCT05979831	Netherton syndrome	12	Randomized, double-Blind, placebo-Controlled •DS-2325 •Placebo	Primary endpoint: safety Secondary endpoint: PK, efficacy, Mean Ichthyosis Area Severity Index (IASI) Scores, Mean Investigator Global Assessment (IGA) Scores, etc.	EU	Dec 2022: Orphan Drug Designation (US) Feb 2023: Fast Track Designation (US) May 2023: Rare Pediatric Disease Designation (US) FPD: Dec 2023

◆ Next Wave (Vaccine)

DS-5670 (mutant strain) (COVID-19 mRNA vaccine)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 jRCT2071220111	Healthy volunteers 12 years and older who have completed primary vaccination of approved COVID-19 vaccine, prevention of COVID-19	1,400	Randomized, single-blind, active-controlled, Main Study and Sub study A (dose validity examination), Sub study B (examination for immunogenicity and safety) <ul style="list-style-type: none"> DS-5670 (omicron variant-adapted bivalent vaccine (original/ omicron BA.4-5)) Comirnaty® RTU (original/ omicron BA.4-5) 	Primary endpoint: Main Study: GMT of blood neutralizing activity against SARS-CoV-2 (Omicron strain) and seroresponse rate at 4 weeks after study drug administration Sub Study A, Sub Study B: not applicable. Secondary endpoint: Main Study: GMT of blood neutralizing activity against SARS-CoV-2 (original strain) and seroresponse rate at 4 weeks after study drug administration, incidence of COVID-19 for 52 weeks after study drug administration, safety Sub Study A, Sub Study B: safety	JP	FSD: May 2023 TLR: Sep 2023 Sep 2023: Filing accepted for monovalent omicron XBB.1.5 (JP) Nov 2023: Approval for monovalent omicron XBB.1.5 (JP)
Phase 3 jRCT2031230424	Healthy volunteers 12 years and older, prevention of COVID-19, single dose	690	Randomized, double-blind, active-controlled <ul style="list-style-type: none"> DS-5670 (XBB.1.5 strain variant-adapted monovalent vaccine) Comirnaty® RTU 	Primary endpoint: GMT and seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older with at least one of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history Secondary endpoint: GMT and seroresponse rate of blood neutralising activity against SARS-CoV-2 (Omicron XBB.1.5) at 4 weeks after the administration in adults and children aged 12 years and older regardless of SARS-CoV-2 infection history and SARS-CoV-2 vaccination history	JP	FSD: Jan 2024 TLR anticipated: FY2024 H1

DS-5670 (mutant strain) (COVID-19 mRNA vaccine)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2/3 jRCT2031220665	Children aged 5 to 11 years who have completed primary vaccination of approved COVID-19 vaccine, prevention of COVID-19	210	Randomized, double-blind, active-controlled, non-inferiority <ul style="list-style-type: none"> DS-5670 (omicron variant-adapted bivalent vaccine (original/ BA.4-5)) Comirnaty® for 5 to 11 years old 	<p>Primary endpoint: GMT of blood neutralizing activity against SARS-CoV-2 (Omicron strain) and seroresponse rate at 4 weeks after study drug administration.</p> <p>Secondary endpoint: GMT of blood neutralizing activity against SARS-CoV-2 (original strain) and seroresponse rate at 4 weeks after study drug administration, Incidence of COVID-19 for 52 weeks after study drug administration, safety</p>	JP	FSD: May 2023 TLR: Feb 2024

VN-0102/JVC-001 (mixed measles-mumps-rubella vaccines)

Trivalent mixed vaccine (MMR vaccine) containing three attenuated viruses of measles, mumps and rubella, which has not been approved in Japan.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-205118	Prevention of measles, mumps and rubella in healthy Japanese children aged 12 months or more and less than 24 months	840	Randomized, double-blind, active-controlled <ul style="list-style-type: none"> VN-0102/ JVC-001 Dry Live Attenuated Measles Rubella vaccine, Freeze-dried Live Attenuated Mumps vaccine 	<p>Primary endpoint: Seroprotection rates for measles, mumps and rubella</p> <p>Secondary endpoint: Seroconversion rates for measles, mumps, and rubella</p>	JP	FSD: Feb 2020 LSD: Sep 2020 Mar 2024: Filing accepted (JP)

VN-0200 (RS virus vaccine)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 NCT05547087 jRCT2071220051	Healthy elderly, prevention of respiratory syncytial (RS) virus infection	340	Randomized, double-blind, dose-comparison <ul style="list-style-type: none"> VN-0200 	<p>Primary endpoint: immunogenicity</p> <p>Secondary endpoint: safety</p>	JP	FSD: Oct 2022 TLR: Dec 2023

◆ **Stage-up Projects (Major Changes from the FY2023 Q3 Financial Announcement in January 2024)**

Generic Name/Project Code Number Mechanism of action	Target Indication	Current Note Stage	
Trastuzumab deruxtecan/DS-8201/T-DXd HER2-directed ADC	HER2+ tumors (IHC3+) , 2L+	Approved	US, DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	NSCLC, 2L/3L	Filed	US/EU, TROPION-Lung01
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	HR positive, HER2 low or negative breast cancer, 2L/3L	Filed	JP/US/EU/China, TROPION-Breast01
Valemetostat/DS-3201 EZH1/2 inhibitor	Relapsed/refractory peripheral T-cell lymphoma	Filed	JP, VALENTINE-PTCL01
VN-0102/JVC-001 mixed measles-mumps-rubella vaccine	Prevention of measles, mumps and rubella	Filed	JP
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	NSCLC, 1L	Ph3 prep	JP/US/EU/Asia, TROPION-Lung10
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	EGFR mutated NSCLC, 1L	Ph3 prep	JP/US/EU/Asia, TROPION-Lung14

◆ **Stage-up Projects (Major Changes from the FY2023 Q3 Financial Announcement in January 2024)**

Generic Name/Project Code Number Mechanism of action	Target Indication	Current Stage	Note
Trastuzumab deruxtecan/DS-8201/T-DXd HER2-directed ADC	HER2 overexpressing tumors	Ph2	China, DESTINY-PanTumor03
Patritumab deruxtecan/U3-1402/HER3-DXd HER3-directed ADC	melanoma, SCCHN, and HER2-negative gastric cancer	Ph2	JP/US/EU/Asia, HERTHENA-PanTumor01
DS-6000/R-DXd CDH6-directed ADC	Platinum-resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer, 2L or later	Ph2/3	JP/US/EU/Asia, REJOICE-Ovarian01
Ifinatamab deruxtecan/DS-7300/ I-DXd B7-H3-directed ADC	endometrial, SCCHN, PDAC, CRC, HCC, esophagus, gastroesophageal junction, and stomach, non-squamous NSCLC, urothelial, 2L or later	Ph2 prep	JP/US/EU/Asia, IDeate-PanTumor02
Ifinatamab deruxtecan/DS-7300/ I-DXd B7-H3-directed ADC	Extensive-stage SCLC, 1L	Ph1b/2 prep	JP/US/EU/Asia, IDeate-Lung03
Valemetostat/DS-3201 EZH1/2 inhibitor	HER2-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma (ENHERTU [®] combo), non-squamous NSCLC (Dato-DXd combo)	Ph1b	JP/US

◆ **Discontinued Project (Major Changes from the FY2023 Q3 Financial Announcement in January 2024)**

Generic Name/Project Code Number Mechanism of action	Target indication	Stage	Discontinued reasons
DS-1594 Menin-MLL binding inhibitor	Acute myeloid leukemia, acute lymphoblastic leukemia	Ph1/2	Decided to discontinue the development based on loss of competitiveness/marketability due to the substantial timeline delay caused by change of competitive situation.